Tag: AML
Syndax’s Revumenib Added to NCCN AML Guidelines Ahead of October 25 FDA Decision
Syndax Pharmaceuticals Inc. (NASDAQ:SNDX) has emerged as a leading contender among the top stocks priced under $20. On…
Why AML patients struggle to get bone marrow transplants
"We are hoping to draw more attention to the disparities that exist in access to potentially life-saving treatments…